DE69112074T2 - Disubstituierte arylverbindungen welche eine selektive leukotrien-b4 antagonistische aktivität aufweisen. - Google Patents

Disubstituierte arylverbindungen welche eine selektive leukotrien-b4 antagonistische aktivität aufweisen.

Info

Publication number
DE69112074T2
DE69112074T2 DE69112074T DE69112074T DE69112074T2 DE 69112074 T2 DE69112074 T2 DE 69112074T2 DE 69112074 T DE69112074 T DE 69112074T DE 69112074 T DE69112074 T DE 69112074T DE 69112074 T2 DE69112074 T2 DE 69112074T2
Authority
DE
Germany
Prior art keywords
selective
leukotria
aryl compounds
antagonistic activity
disubstituted aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69112074T
Other languages
English (en)
Other versions
DE69112074D1 (de
Inventor
Fu-Chih Huang
Wan Chan
Charles Sutherland
Robert Galemmo
Michael Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer International Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer International Holdings Inc filed Critical Rhone Poulenc Rorer International Holdings Inc
Application granted granted Critical
Publication of DE69112074D1 publication Critical patent/DE69112074D1/de
Publication of DE69112074T2 publication Critical patent/DE69112074T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69112074T 1990-09-24 1991-09-06 Disubstituierte arylverbindungen welche eine selektive leukotrien-b4 antagonistische aktivität aufweisen. Expired - Lifetime DE69112074T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/586,830 US5210208A (en) 1990-09-24 1990-09-24 Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity
PCT/US1991/006446 WO1992005145A1 (en) 1990-09-24 1991-09-06 Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity

Publications (2)

Publication Number Publication Date
DE69112074D1 DE69112074D1 (de) 1995-09-14
DE69112074T2 true DE69112074T2 (de) 1996-01-11

Family

ID=24347270

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69112074T Expired - Lifetime DE69112074T2 (de) 1990-09-24 1991-09-06 Disubstituierte arylverbindungen welche eine selektive leukotrien-b4 antagonistische aktivität aufweisen.

Country Status (9)

Country Link
US (1) US5210208A (de)
EP (1) EP0554313B1 (de)
JP (1) JP3368565B2 (de)
AT (1) ATE126205T1 (de)
AU (1) AU650825B2 (de)
CA (1) CA2092306C (de)
DE (1) DE69112074T2 (de)
MX (1) MX9203751A (de)
WO (1) WO1992005145A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8641991A (en) * 1990-09-10 1992-03-30 Rhone-Poulenc Rorer International (Holdings) Inc. Substituted bicyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity
JPH0741421A (ja) * 1993-05-28 1995-02-10 Suntory Ltd ロイコトリエンｂ４ （ｌｔｂ４ ）による医学的症状の予防及び改善剤
FR2705959B1 (fr) * 1993-06-01 1995-08-11 Oreal Procédé de synthèse stéréospécifique de leucotriène B4 sous sa configuration 6Z, 8E, 10E et produits intermédiaires.
JPH11507669A (ja) 1995-06-12 1999-07-06 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ−２インヒビターとロイコトリエンｂ▲下４▼受容体アンタゴニストの組合せによる炎症と炎症関連疾患の治療
ATE296114T1 (de) * 1996-02-13 2005-06-15 Searle & Co Zubereitungen, enthaltend einen cyclooxygenase-2- inhibitor und einen leukotrien-b4-rezeptor- antagonisten
WO1998013347A1 (en) 1996-09-26 1998-04-02 Novartis Ag Aryl-substituted acrylamides with leukotriene b4 (ltb-4) receptor antagonist activity
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) * 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
WO2008012246A1 (de) 2006-07-24 2008-01-31 Basf Se Azolylmethyloxirane, ihre verwendung zur bekämpfung von pflanzenpathogenen pilzen sowie sie enthaltende mittel
BRPI0714974A2 (pt) 2006-07-25 2013-03-26 Basf Se compostos, uso de compostos, composiÇço para a proteÇço de colheita, semente, e, processo para combater fungos fitopatogÊnicos
WO2008077724A1 (de) 2006-12-22 2008-07-03 Basf Se Azolylmethyloxirane, ihre verwendung zur bekämpfung von pflanzenpathogenen pilzen sowie sie enthaltende mittel
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
WO2012054367A1 (en) 2010-10-19 2012-04-26 Boehringer Ingelheim International Gmbh Rho kinase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191824A (en) * 1976-02-04 1980-03-04 The Upjohn Company 5-Halo PGI compounds
US4216238A (en) * 1979-02-13 1980-08-05 Stauffer Chemical Company Dialkyl amino ethyl amides, their salts and their use as anti-ripening agents
US4727180A (en) * 1979-07-26 1988-02-23 E. I. Du Pont De Nemours And Company Antihypertensive polyhalohydroxylisopropyl phenylalkanoic and phenylalkenoic acids, amides and esters and intermediates thereto
US5140046A (en) * 1985-04-03 1992-08-18 Yamanouchi Pharmaceutical Co., Ltd. Phenylene derivatives, compositions and use
US4820722A (en) * 1987-08-14 1989-04-11 Eli Lilly And Company Disubstituted tetrazoles and their use as leukotriene antagonists

Also Published As

Publication number Publication date
EP0554313A1 (de) 1993-08-11
EP0554313B1 (de) 1995-08-09
CA2092306A1 (en) 1992-03-25
ATE126205T1 (de) 1995-08-15
AU650825B2 (en) 1994-06-30
WO1992005145A1 (en) 1992-04-02
EP0554313A4 (en) 1994-05-18
JPH06502164A (ja) 1994-03-10
JP3368565B2 (ja) 2003-01-20
US5210208A (en) 1993-05-11
AU8761091A (en) 1992-04-15
CA2092306C (en) 2004-11-16
DE69112074D1 (de) 1995-09-14
MX9203751A (es) 1992-09-01

Similar Documents

Publication Publication Date Title
DE69112074D1 (de) Disubstituierte arylverbindungen welche eine selektive leukotrien-b4 antagonistische aktivität aufweisen.
RU93058531A (ru) Фторалкоксибензиламинные производные азотсодержащих гетероциклов, фармацевтическая композиция, способ лечения
NO156373C (no) AnalogifremgangsmŸte for fremstilling av terapeutisk aktive furo-(3,4-c)-pyridinderivater.
NO880182L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,2-dihydro-3h-indazol-3-on-derivater.
NO874032D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive catecholderivater.
DE68907423D1 (de) Behandlung der akne.
DE69112062T2 (de) Substituierte monocyclische anylderivate mit selektiver leukotrien b4 antagonistischer wirkung.
DE3684755D1 (de) Behandlung von tieren mit il-2, zubereitungen dafuer und ihre herstellung.
NO864130D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive karboksamid-derivater.
NO883122L (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylamid-derivater.
NO171909C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,4-dihydropyridinderivater
NO875488D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive alkansulfonanilid-derivater.
DE3786562D1 (de) 2,6-dideoxy-2-fluoro-l-talopyranose, derivate davon und herstellung dieser verbindungen.
DE69621786T2 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
DE336374T1 (de) Behandlung von zusammensetzungen von polyimid-vorlaeufern.
NO881768L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksaner.
DK229984D0 (da) 4-oxothiazolidin-2-yliden-acetamid-derivater
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
ES2061775T3 (es) Derivados de estrobirulina, su obtencion y empleo.
NO893768L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 2,7-diamino-1,2,3,4-tetrahydronaftalenderivater.
NO871907D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive alkenamid-derivater.
SE8703308L (sv) Terapeutiskt medel for behandling av sjukdomar forbundna med cerebral ischemi
DE3669159D1 (de) Triazinderivate, verfahren zur herstellung dieser derivate und herbizide, welche diese derivate als wirksame komponente enthalten.
DE58906571D1 (de) 2-Aminocarbonsäuren und deren Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel.
NO882282D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrazin-amider.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8339 Ceased/non-payment of the annual fee
8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS PHARMA S.A., ANTONY, FR

8370 Indication related to discontinuation of the patent is to be deleted